非布索坦组严重不良反应在数量上多于安慰剂组，但是没有统计学上的显著性差异。
The incidence of serious adverse events was numerically higher with febuxostat than with placebo, but the difference between treatments was not statistically significant.
非布索坦组严重不良反应在数量上多于安慰剂组，但是没有统计学上的显著性差异。
The incidence of serious adverse events was numerically higher with febuxostat than with placebo, but the difference between treatments was not statistically significant.
应用推荐